Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)
China
· Delayed Price · Currency is CNY 35.25
+0.47 (1.35%)
At close: Apr 29, 2026
SHA:688163 Revenue
Shanghai Serum Bio-Technology had revenue of 27.09M CNY in the quarter ending March 31, 2026, with 5.75% growth. This brings the company's revenue in the last twelve months to 197.68M, up 1.77% year-over-year. In the year 2025, Shanghai Serum Bio-Technology had annual revenue of 196.21M with 0.66% growth.
Revenue (ttm)
197.68M
Revenue Growth
+1.77%
P/S Ratio
19.30
Revenue / Employee
606.37K
Employees
324
Market Cap
3.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 196.21M | 1.29M | 0.66% |
| Dec 31, 2024 | 194.92M | 4.77M | 2.51% |
| Dec 31, 2023 | 190.14M | 15.92M | 9.14% |
| Dec 31, 2022 | 174.22M | -34.47M | -16.52% |
| Dec 31, 2021 | 208.69M | 23.13M | 12.47% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guanhao Biotech | 387.75M |
| Zhejiang Wecome Pharmaceutical Company | 131.67M |
| Qingdao Vland Biotech INC. | 1.37B |
| Baolingbao Biology | 2.81B |
| Zhejiang Shouxiangu Pharmaceutical | 642.66M |
| Shanghai Shen Lian Biomedical | 288.27M |
| Hinova Pharmaceuticals | 46.50M |
| Boji Medical Technology | 949.94M |